✦ LIBER ✦

Translational development of active immunotherapy for hematologic malignancies

✍ Scribed by Larry W. Kwak

Publisher: Carden Jennings Publishing
Year: 2002
Tongue: English
Weight: 340 KB
Volume: 76
Category: Article
ISSN: 0925-5710
DOI: 10.1007/bf03165274

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Immunotherapy of malignant diseases – de

Immunotherapy of malignant diseases – developments and prospects

✍ Patricia Paukovits; Gottfried Himmler; Hans Loibner 📂 Article 📅 2004 🏛 Springer Vienna 🌐 German ⚖ 89 KB

Immunotherapy for malignant gliomas: emp

Immunotherapy for malignant gliomas: emphasis on strategies of active specific immunotherapy using autologous dendritic cells

✍ Steven De Vleeschouwer; Stefaan W. Van Gool; Frank Van Calenbergh 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 478 KB

Mammalian target of rapamycin inhibition

Mammalian target of rapamycin inhibition as therapy for hematologic malignancies

✍ Corey Cutler; Joseph H. Antin 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 32 KB

P anwalkar and colleagues present a very complete overview on the evolving role of mammalian target of rapamycin (mTOR) inhibitors in the treatment of both hematologic and nonhematologic malignancies. We wish to clarify selected statements made by the authors. We would like to point out that all mT

Mammalian target of rapamycin inhibition

Mammalian target of rapamycin inhibition as therapy for hematologic malignancies

✍ Amit Panwalkar; Srdan Verstovsek; Francis J. Giles 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 588 KB

## Abstract The mammalian target of rapamycin (mTOR) is a downstream effector of the phosphatidylinositol 3‐kinase (PI3K)/Akt (protein kinase B) signaling pathway, which mediates cell survival and proliferation. mTOR regulates essential signal‐transduction pathways, is involved in the coupling of g

Experimental trials of immunotherapy for

Experimental trials of immunotherapy for malignant melanoma

✍ Douglas Reintgen; Jeanne Becker; Hilliard F. Seigler 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 809 KB

Conventional treatment for metastatic melanoma consists of surgical resection, chemotherapy, and radiation therapy. New approaches toward treatment of this disease include the development of passive and active immunotherapeutic regimens. Malignant melanoma is particularly amendable to immunotherapy

The role of Src in solid and hematologic

The role of Src in solid and hematologic malignancies : Development of new-generation Src inhibitors

✍ Ricardo H. Alvarez; Hagop M. Kantarjian; Jorge E. Cortes 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 327 KB

## Abstract __c‐Src__ was the first protooncogene described and was among the first molecules in which tyrosine kinase activity was documented. c‐Src has been defined as a common modular structure that participates in much of the crosstalk between the cytoplasmic protein tyrosine kinases and tyrosi